Literature DB >> 23462752

Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration.

Ruozhou Tom Liu1, Jiangyuan Gao, Sijia Cao, Navroop Sandhu, Jing Z Cui, Chai Lin Chou, Edward Fang, Joanne A Matsubara.   

Abstract

PURPOSE: Drusen are hallmarks of age-related macular degeneration (AMD). Amyloid-beta 1-40 (Aβ 1-40), a constituent of drusen, is known to stimulate inflammatory pathways in RPE; however, its effect in vivo is not known. The purpose of this study was to examine the effect of Aβ 1-40 on cytokine expression and inflammasome activation relevant to AMD in an animal model.
METHODS: Wild-type rats received intravitreal injections of Aβ 1-40, and eyes were taken at days 1, 4, 14, and 49 postinjection. The RPE, neuroretina, and vitreous were analyzed for cytokine expression, inflammasome activation, and microglial response via RT-PCR, immunohistochemistry, and suspension array assay. Retinal cell loss was assessed via apoptotic markers and retinal thickness.
RESULTS: Aβ 1-40 stimulated upregulation of IL-6, TNF-α, IL-1β, IL-18, caspase-1, NLRP3, and XAF1 genes in the RPE/choroid and the neuroretina. Increased IL-1β and IL-6 immunoreactivity was found in retinal sections, and elevated levels of IL-1β and IL-18 were found in the vitreous of Aβ-injected eyes. Aβ 1-40 induced a moderate increase in CD11b/c-reactive cells on day 1 postinjection only. No evidence of the proapoptotic XAF1 protein, p53, TUNEL immunoreactivity, or retinal thinning was observed.
CONCLUSIONS: These results confirm earlier in vitro work and support the proinflammatory role of drusen component Aβ 1-40 in the RPE and retina. Inflammasome activation may be responsible for this effect in vivo. This model is useful for understanding cellular triggers of inflammasome activation and proposed early inflammatory events in the outer retina associated with the etiology of AMD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462752      PMCID: PMC3947398          DOI: 10.1167/iovs.12-10849

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  65 in total

1.  Xaf1 can cooperate with TNFalpha in the induction of apoptosis, independently of interaction with XIAP.

Authors:  Yan Xia; Rachel Novak; Jennifer Lewis; Colin S Duckett; Andrew C Phillips
Journal:  Mol Cell Biochem       Date:  2006-01-24       Impact factor: 3.396

2.  Early features of AMD.

Authors:  Ruth E Hogg; Michael R Stevenson; Usha Chakravarthy; Raymond O Beirne; Roger S Anderson
Journal:  Ophthalmology       Date:  2007-05       Impact factor: 12.079

3.  Increased cytokine gene expression in rat retina following transient ischemia.

Authors:  M Hangai; N Yoshimura; Y Honda
Journal:  Ophthalmic Res       Date:  1996       Impact factor: 2.892

4.  Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration.

Authors:  G Malek; L V Johnson; B E Mace; P Saloupis; D E Schmechel; D W Rickman; C A Toth; P M Sullivan; C Bowes Rickman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-03       Impact factor: 11.205

5.  Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in age-related macular degeneration.

Authors:  Jiying Wang; Kyoko Ohno-Matsui; Takeshi Yoshida; Noriaki Shimada; Shizuko Ichinose; Tetsuji Sato; Manabu Mochizuki; Ikuo Morita
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

6.  Interleukin-6 (IL-6) gene expression and secretion by cytokine-stimulated human retinal pigment epithelial cells.

Authors:  V M Elner; W Scales; S G Elner; J Danforth; S L Kunkel; R M Strieter
Journal:  Exp Eye Res       Date:  1992-03       Impact factor: 3.467

7.  Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas.

Authors:  Tzvete Dentchev; Ann H Milam; Virginia M-Y Lee; John Q Trojanowski; Joshua L Dunaief
Journal:  Mol Vis       Date:  2003-05-14       Impact factor: 2.367

8.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Stacy M Meuer; Guan-Hua Huang
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

9.  The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration.

Authors:  Lincoln V Johnson; William P Leitner; Alexander J Rivest; Michelle K Staples; Monte J Radeke; Don H Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-20       Impact factor: 11.205

10.  Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat.

Authors:  Peter Jb Anderson; Hr Watts; Cj Hille; Kl Philpott; P Clark; M Croucher S Gentleman; Ling-Sun Jen
Journal:  Clin Ophthalmol       Date:  2008-12
View more
  55 in total

1.  Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin.

Authors:  Rajni Parthasarathy; K Martin Chow; Zahra Derafshi; Michael P Fautsch; John R Hetling; David W Rodgers; Louis B Hersh; David R Pepperberg
Journal:  Exp Eye Res       Date:  2015-07-02       Impact factor: 3.467

2.  Association of Anticholinergic Drug Use With Risk for Late Age-Related Macular Degeneration.

Authors:  Gauthier Aldebert; Jean-Luc Faillie; Dominique Hillaire-Buys; Thibault Mura; Isabelle Carrière; Cécile Delcourt; Catherine Creuzot-Garcher; Max Villain; Vincent Daien
Journal:  JAMA Ophthalmol       Date:  2018-07-01       Impact factor: 7.389

3.  Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells.

Authors:  Ruozhou Tom Liu; Aikun Wang; Eleanor To; Jiangyuan Gao; Sijia Cao; Jing Z Cui; Joanne A Matsubara
Journal:  Exp Eye Res       Date:  2014-07-17       Impact factor: 3.467

Review 4.  Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit.

Authors:  Islam N Mohamed; Tauheed Ishrat; Susan C Fagan; Azza B El-Remessy
Journal:  Antioxid Redox Signal       Date:  2014-11-11       Impact factor: 8.401

5.  Iron Toxicity in the Retina Requires Alu RNA and the NLRP3 Inflammasome.

Authors:  Bradley D Gelfand; Charles B Wright; Younghee Kim; Tetsuhiro Yasuma; Reo Yasuma; Shengjian Li; Benjamin J Fowler; Ana Bastos-Carvalho; Nagaraj Kerur; Annette Uittenbogaard; Youn Seon Han; Dingyuan Lou; Mark E Kleinman; W Hayes McDonald; Gabriel Núñez; Philippe Georgel; Joshua L Dunaief; Jayakrishna Ambati
Journal:  Cell Rep       Date:  2015-06-11       Impact factor: 9.423

6.  Effect of Aβ protein on inhibiting proliferation and promoting apoptosis of retinal pigment epithelial cells.

Authors:  Zi Ye; Shou-Zhi He; Zhao-Hui Li
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

7.  Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation.

Authors:  Cristhian J Ildefonso; Henrique Jaime; Masmudur M Rahman; Qiuhong Li; Shannon E Boye; William W Hauswirth; Alexandra R Lucas; Grant McFadden; Alfred S Lewin
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

8.  NLRP3 inflammasome in NMDA-induced retinal excitotoxicity.

Authors:  Pavlina Tsoka; Paulo R Barbisan; Keiko Kataoka; Xiaohong Nancy Chen; Bo Tian; Peggy Bouzika; Joan W Miller; Eleftherios I Paschalis; Demetrios G Vavvas
Journal:  Exp Eye Res       Date:  2019-01-29       Impact factor: 3.467

Review 9.  Immunology of age-related macular degeneration.

Authors:  Jayakrishna Ambati; John P Atkinson; Bradley D Gelfand
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

10.  Amyloid beta deposition related retinal pigment epithelium cell impairment and subretinal microglia activation in aged APPswePS1 transgenic mice.

Authors:  Zhi-Zhang Dong; Juan Li; Yi-Feng Gan; Xue-Rong Sun; Yun-Xia Leng; Jian Ge
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.